A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Phase 1

Mersana Therapeutics